Journal articles: '321.804 3'

1

le Coutre, Philipp D., Francis J. Giles, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, et al. "Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,." Blood 118, no. 21 (November 18, 2011): 3770. http://dx.doi.org/10.1182/blood.v118.21.3770.3770.

Full text

Abstract:

Abstract Abstract 3770 Background: Nilotinib is a selective and potent BCR-ABL TKI approved for the treatment of pts with newly diagnosed Ph+ CML-CP, and for pts with CML-CP or CML-AP resistant to or intolerant of imatinib. Here, we present the 48-mo follow-up data from the 2101 trial for pts with imatinib resistance or intolerance. Methods: Pts were treated with nilotinib 400 mg twice daily (BID). Key endpoints included PFS (defined as progression to AP/BC or discontinuation due to disease progression as assessed by investigator or death from any cause) and OS (includes deaths during treatment or follow-up after discontinuation). Results: 321 pts were enrolled (70% imatinib resistant; 30% imatinib intolerant with resistance). At baseline (BL), 36% of pts were in CHR. At the time of data cutoff, 224/321 pts (70%) discontinued nilotinib therapy (Table), and 31% of all pts had at least 48 mo of treatment. The median nilotinib dose intensity was 789 mg/day (range, 151–1110) and 62% of pts received ≥ 400 mg BID nilotinib as their last dose available. Pts with BL CHR had a significantly higher PFS rate at 48 mo vs pts without BL CHR (71% vs 49%, respectively; P =.001). Only 11 (3%) pts progressed to advanced disease (AP/BC) during study. Estimated 48-mo OS rate was 78% (95% CI 74%-83%). Among resistant pts, those without BL mutations (n = 92) had a significantly higher OS rate at 48 mo vs pts with sensitive mutations at BL (n = 78) (84% vs 74%, respectively, P =.029); however, there was no significant difference in OS among pts with sensitive and insensitive mutations (Y253H, E255K/V or F359C/V, n = 27) at BL (74% vs 71%, respectively, P =.804). No new safety signals were observed, and few additional AEs were reported since 24 mo follow-up (Table). Biochemical lab abnormalities were generally mild, transient, and easily managed; grade 3/4 lipase elevation (19%), hypophosphatemia (18%), and hyperglycemia (13%) were most common. Reports of any-grade pleural effusions remained low (1%), and no new cases were reported with longer follow-up. No new cases of QTcF >500 ms and 3 new cases of QTcF increases > 60 ms from BL were reported. Nine pts died during treatment or within 28 days of discontinuation: 8 deaths were previously reported and occurred in the first 24 mo of follow-up; 1 additional death due to lung neoplasm occurred between 24 and 48 mo (35 mo). Conclusions: With longer follow up, nilotinib continues to be effective and well tolerated in pts with Ph+ CML-CP resistant to or intolerant of imatinib therapy. Nilotinib prevented progression to AP/BC in the majority of pts on treatment and was associated with high OS rates. No cumulative toxicity was observed. Data demonstrating the higher rate of PFS in pts who entered the study with a BL CHR suggest that switching pts to nilotinib prior to hematologic failure on imatinib, and according to current treatment guidelines, may maximize the efficacy of nilotinib therapy. Disclosures: le Coutre: Novartis: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria. Giles:Novartis: Consultancy, Honoraria, Research Funding. Pinilla-Ibarz:Novartis: Research Funding, Speakers Bureau. Larson:Novartis: Consultancy, Honoraria, Research Funding. Gattermann:Novartis: Honoraria, Research Funding. Ottmann:Novartis: Consultancy; BMS: Consultancy, Research Funding. Hochhaus:Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Ariad: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria, Research Funding. Radich:BMS: Consultancy; Novartis: Consultancy, Research Funding. Saglio:Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Pfizer: Consultancy. Hughes:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Ariad: Honoraria, Membership on an entity's Board of Directors or advisory committees. Martinelli:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Pfizer: Consultancy. Kim:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding. Branford:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Research Funding; Ariad: Research Funding. Müller:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Shou:Novartis: Employment. Novick:Novartis: Employment, Equity Ownership. Fan:Novartis: Employment. Cortes:Novartis: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Ariad: Consultancy, Research Funding. Baccarani:Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau. Kantarjian:Novartis: Consultancy, Research Funding; BMS: Research Funding; Pfizer: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

2

Mounce, Luke TA, Willie Hamilton, and Sarah ER Bailey. "Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care." British Journal of General Practice 70, no. 698 (July 27, 2020): e622-e628. http://dx.doi.org/10.3399/bjgp20x710957.

Full text

Abstract:

BackgroundA raised platelet count (thrombocytosis) measuring >400 × 109/l is associated with high cancer incidence. It is uncertain whether platelet counts at the upper end of the normal range (high-normal: 326–400 × 109/l) are also associated with cancer.AimTo investigate cancer incidence following a normal platelet count in primary care.Design and settingA prospective cohort study was undertaken using data from the Clinical Practice Research Datalink and National Cancer Registration and Analysis Service, dating from 1 May 2005 to 30 April 2014.MethodOne-year cancer incidence was estimated for 295 312 patients with normal platelet counts (150–400 × 109/l). Patients with platelet counts >325 × 109/l were oversampled to maximise precision of estimates of cancer incidence. All patients were aged ≥40 years with no prior cancer diagnoses. The effects of age, sex, and smoking were explored. Non-melanoma skin cancers were omitted from exclusions and incidence.ResultsOne-year cancer incidence increased greatly with age, male sex, and higher platelet count. Males aged ≥60 years with a high-normal count had an incidence of 4.2% (95% confidence interval [CI] = 4.0 to 4.4). The highest incidence of 6.7% (95% CI = 5.3 to 8.4) was found in males aged ≥80 years, who had platelets in the range of 376–400 × 109/l; this was 3.1 percentage points higher than the incidence for patients in the same age group with lower-normal counts of 150–325 × 109/l. Risks for all female subgroups were <3%. Patients with high-normal platelet counts were most at risk of lung and colorectal cancers and, in general, had advanced-stage cancer at diagnosis.ConclusionPlatelet counts at the high-normal range in males aged ≥60 years may be indicative of an underlying malignancy, and referral for further investigation should be considered.

APA, Harvard, Vancouver, ISO, and other styles

3

Ollivierz, L. "Genetic differences in recombination frequency in the pig (Sus scrofa)." Genome 38, no. 5 (October 1, 1995): 1048–51. http://dx.doi.org/10.1139/g95-139.

Full text

Abstract:

A comparison has been performed on 3 recently published linkage maps of the pig, hereafter designated as the American (A), European (E), and Swedish (S) maps. The cumulated distances between common markers in these 3 maps were in the ratio 1.00 (A): 0.88 (E): 0.77 (S), in keeping with the ratio of the percentages of domestic genome in the reference families used to build the corresponding maps, i.e., 1.00 (A): 0.81 (E): 0.50 (S). From further recombination frequencies reported in wild boars (in the S report), the wild pig genome length (in centimorgans) is expected to represent 66% of the domestic pig genome length. These observations tend to confirm a general result of Burt and Bell (Nature (London), 326: 803–805 (1987)), showing higher chiasma frequencies in domestic mammalian species compared with wild species. Consequences for mapping studies are discussed.Key words: recombination, pig, microsatellites, chiasmata.

APA, Harvard, Vancouver, ISO, and other styles

4

Cada, Dennis J., Terri L. Levien, and Danial E. Baker. "Perampanel." Hospital Pharmacy 48, no. 4 (April 2013): 321–31. http://dx.doi.org/10.1310/hpj4804-321.

Full text

Abstract:

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2013 monograph topics are alogliptin, crofelemer, lomitapide, ponatinib, and sumatriptan iontophoretic transdermal. The DUE/MUE is on alogliptin.

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, S., M. C. Ha-Thi, and R. Schläfer. "311 Lysyl Oxidase Antagonizes RAS Oncogene-mediated Transformation." European Journal of Cancer 48 (July 2012): S76. http://dx.doi.org/10.1016/s0959-8049(12)71004-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Cain, Joe. ": Aydon, C.Charles Darwin. Robinson, London: 2003. Pp xxvi, 326. Price £ 7.99. ISBN 1-84119-801-3 (paperback)." Archives of Natural History 31, no. 2 (April 2005): 369–70. http://dx.doi.org/10.3366/anh.2005.31.2.369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chadwick, Owen. "Theologische Realenzyklopädie, xiv. Gottesdienst–Heimat. Edited by Gerhard Müller. Pp. 804 + 39 ills, and 3 maps. Berlin–New York: Walter de Gruyter, 1985. DM 320. 3 11 008583 6." Journal of Ecclesiastical History 37, no. 4 (October 1986): 664–65. http://dx.doi.org/10.1017/s0022046900022442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Abou-Alfa, G. K., J. A. O'Donoghue, B. Gansukh, J. Ma, S. Ruan, M. Koga, R. Lee, N. Ohishi, T. Othomo, and J. A. Carrasquillo. "328 124I GC33 Positron Emission Tomography (PET), Imaging Biomarker of Glypican-3 in Hepatocellular Carcinoma." European Journal of Cancer 48 (November 2012): 100. http://dx.doi.org/10.1016/s0959-8049(12)72126-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

ZHANG, JIANJUN, and JUNHONG DUAN. "SYNTHESIS AND CHARACTERIZATION OF SPHERE-LIKE ZnS NANOCRYSTALS BY THERMOLYSIS OF A NEW COMPLEX PRECURSOR." Modern Physics Letters B 24, no. 19 (July 30, 2010): 2091–99. http://dx.doi.org/10.1142/s0217984910024456.

Full text

Abstract:

In this paper, the preparation and optical properties of sphere-like ZnS nanocrystals are reported. Pure and uniform cubic-phase sphere-like ZnS nanocrystals with grain sizes of 30–40 nm were synthesized by thermolysis of a new precursor complex ( enH 2)0.5[ Zn ( en )3]( SCN )3 (en = ethylenediamine) in nitrogen stream at 800°C. The as-synthesized products were characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS) and X-ray photoelectron spectroscopy (XPS), respectively. The XRD analysis reveals the phase of ZnS with cubic zinc blende. UV-Vis and photoluminescence spectra (PL) were utilized to investigate the optical properties of sphere-like ZnS nanocrystals. By testing on UV-Vis spectra, it is concluded that the limiting wavelength of the ZnS nanocrystals is 320 nm and the band gap is 3.88 eV. In room temperature PL spectra, one strong emission peak centered at 322 nm is discovered, which could be attributed to the band to band transitions. The above-mentioned results showed that the thermolysis method is preferable for synthesizing high-quality sphere-like ZnS nanocrystals. The synthesized precursor could be used as morphological templates to prepare nanostructure inorganic compounds.

APA, Harvard, Vancouver, ISO, and other styles

10

Yasuda, Y., H. Furusawa, Y. Maeda, and K. Komaki. "327 The Serum HER-2 Reflects the Tumor Burden of Breast Cancer." European Journal of Cancer 48 (March 2012): S138. http://dx.doi.org/10.1016/s0959-8049(12)70393-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Siniscalchi, C., E. Mariotti, L. Boccia, G. Albero, S. Di Francesco, M. V. Suárez, R. Di Palo, and B. Gasparrini. "321 CO-CULTURE WITH OVIDUCT EPITHELIAL CELLS PROMOTES CAPACITATION OF BUFFALO (BUBALUS BUBALIS) SPERM." Reproduction, Fertility and Development 22, no. 1 (2010): 316. http://dx.doi.org/10.1071/rdv22n1ab321.

Full text

Abstract:

The process of capacitation, necessary for spermatozoa to acquire fertilizing ability, normally takes place in the oviduct. It has been demonstrated that oviduct fluid improves capacitation in bovine spermatozoa (McNutt TL and Killian GJ 1991 J. Androl. 12, 244-252). The aim of this study was to evaluate whether co-culturing buffalo sperm with bovine oviduct epithelial cells (BOEC) promotes in vitro capacitation of buffalo spermatozoa. Bovine oviducts were obtained at a local abattoir from cows that were in the preovulatory phase of a normal estrous cycle. BOEC recovered as previously described (Gualtieri R and Talevi R 2000 Biol. Reprod. 62, 1754-1762) from 5 oviducts were pooled and plated in dishes of TCM-199 + 10% FCS, 100 U mL-1 penicillin, 100 μg mL-1 streptomycin, and 0.25 μg mL-1 amphotericin B. Medium was changed every 48 h up to Day 6, when cell confluence and cilia activity were optimal. On day of trial, the medium was removed from the BOEC dishes and replaced with modified TALP containing 30 μM penicillamine, 15 μM hypotaurin, 0.15 μM epinephrine, and 1% bovine serum (mTALP). Buffalo frozen- thawed sperm from 4 bulls, pooled and treated by Percoll gradients, were incubated for 3 h (1 million sperm/mL): in mTALP with 30 μg mL-1 of heparin (Group A), on the BOEC monolayer (Group B), on the BOEC monolayer with 30 μg mL-1 of heparin (Group C), and in medium lacking capacitating agents, as negative control (Group D). After 3 h, sperm were recovered by centrifugation and capacitation was indirectly evaluated by assessing their ability to undergo acrosome reaction (AR) after 10 min of exposure to 10 μM calcium ionophore A23187. The AR was determined by the double-staining technique with trypan blue-Giemsa (Kovács A andFoote RH 1992 Biotec. Histochem. 67, 119-124). Spermatozoa (n = 294, 204, 225, and 222 for Groups A, B, C, and D, respectively) were then examined by microscopic evaluation. Differences in the percentages of AR among groups were analyzed by chi-square test. After Percoll separation, sperm viability was 95.8% and acrosomal loss was observed only in 5% of the sperm population. After 3 h of incubation, sperm viability decreased (P < 0.01) in all groups compared to the post-Percoll time, whereas no differences were found among groups (73, 80.4, 80.0, and 76.2%, respectively, for Groups A, B, C, and D). Sperm co-incubation with both BOEC and heparin for 3 h improved capacitation, as indicated by the significant increase (P < 0.01) of AR compared to the negative control (29.9, 30.5, 30.6, and 14%, respectively, for Groups A, B, C, and D). Furthermore, both BOEC groups gave percentages of AR similar to those observed after incubation with heparin, that is, the most widely used capacitating agent. In conclusion, it was demonstrated that co-culturing sperm with BOEC, both in the presence or absence of heparin, enhances buffalo sperm capacitation in vitro.

APA, Harvard, Vancouver, ISO, and other styles

12

Garrett, C. R., L. L. Siu, G. Giaccone, A. El-Khoueiry, J. Marshall, P. LoRusso, L. Velasquez, G. Kollia, P. He, and D. Feltquate. "A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14018. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14018.

Full text

Abstract:

14018 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Prior studies have validated both VEGF and EGF signaling pathways as targets in AGM. The MTD of single-agent brivanib is 800 mg qd (ASCO #3051, 2006). Methods: An open-label Phase I dose-escalation study of brivanib in combination with cetuximab was conducted in pts with AGM who failed prior therapy. Brivanib was given po Day 1 and qd from Day 8, starting at 320 mg. Cetuximab was given IV Day 8 (400 mg/m2) then weekly (250 mg/m2). Dose escalation of brivanib continued to 800 mg qd, when an expansion cohort for pts with colorectal cancer (CRC) was opened for additional safety and efficacy. Fresh tissue and blood sampling for biomarker and pharmacokinetic (PK) analysis was performed. FDG-PET was obtained at Baseline X 2, Days 15 and 56. Tumor response (modified WHO) was evaluated q 8 weeks. Results: 18 pts (15 CRC, 2 esophageal, 1 other) were treated with 320, 600 or 800 mg qd of brivanib in combination with cetuximab for a median of 8 weeks (range 1 - 20+). A single DLT, bilateral pulmonary emboli, occurred at 320 mg qd. Few treatment-related AEs occurred across the 3 cohorts (Table). PK/biomarker data is pending. Available FDG-PET results from measurements in 8 pts with 2–3 target lesions showed good baseline reproducibility in SUVpeak, SUVmean and SUVmax, with intra-subject CV of 3.6%, 7.2% and 9.3%, respectively. Conclusions: Brivanib in combination with full-dose cetuximab was well tolerated at ≤800 mg qd and did not result in enhancement of cetuximab associated AEs. Pre-treatment FDG-PET is a highly reproducible imaging modality. [Table: see text] [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

13

Bodei, Lisa, Mark Kidd, Chiara M. Grana, Ignat Drozdov, Irvin Modlin, and Giovanni Pagnelli. "325 Factors Influencing the Development of Toxicity After Peptide Radio-Receptor Therapy for NETs: an Evaluation of 807 Patients." Gastroenterology 146, no. 5 (May 2014): S—73. http://dx.doi.org/10.1016/s0016-5085(14)60266-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Su, Hang, Yongping Song, Wenqi Jiang, Xiuhua Sun, Wenbin Qian, Wei Zhang, Yuhuan Gao, et al. "Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 8034. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8034.

Full text

Abstract:

8034 Background: Sintilimab, a programmed death-1 checkpoint inhibitor, has demonstrated efficacy in relapsed/refractory cHL after the primary analysis of the ORIENT-1 study. Here, we report the updated safety and efficacy profile after long-term follow-up. Methods: ORIENT-1 is a multicenter, single-arm, phase II study in China. Classical Hodgkin’s lymphoma patients who had failed ≥2 lines of systemic therapy, including autologous hematopoietic stem cell transplantation (HSCT) were enrolled. Sintilimab, 200 mg IV was given every 3 weeks, until disease progression, death, unacceptable toxicity, or withdrawal from study. The primary endpoint objective response rate (ORR) by an independent radiological review committee (IRRC) per IWG 2007 has been reported before. The progression free survival (PFS) by IRRC follow-up data are reported herein. Results: 96 patients were treated. As of the data cutoff on 30 Sep, 2019, 57.3 % patients complete two-year treatment, with a median follow-up of 26.7 months. The median duration of treatment was 24.1 months (range: 0.7 to 24.8). Of 49 patients with progressive disease (PD) by investigator, 39/49 (79.6%) patients received treatment beyond PD, with a median treatment duration after PD of 8.0 months (range: 1.4 to 20.8). The median PFS was 18.6 months (95%CI: 14.4 to 22.3). Median overall survival has not been reached. Two-year OS rate was 96.3% (95%CI: 88.9% to 98.8%). The treatment-related adverse event (TRAE) was reported in 92/96 (95.8%) patients, most (71/96, 74.0%) of which were grade 1-2. The most common grade 3 or 4 TRAEs were pyrexia (3/96, 3.1%), lipase increased (3/96, 3.1%) and lymphocyte decreased (3/96, 3.1%). Conclusions: The results from long-term follow-up showed that, in addition to a high rate of response, sintilimab also demonstrated durable efficacy and favorable long-term safety profile. Considering the high rate (nearly 80%) of treatment beyond PD, IWG 2007 which was used to evaluate PFS may not be a suitable criteria for evaluating the efficacy of anti-PD-1 antibody in cHL. Further investigation and analysis are required. Clinical trial information: NCT03114683 .

APA, Harvard, Vancouver, ISO, and other styles

15

Ohtsu, A., and T. Doi. "328 INVITED Lessions From Global Clinical Trials for Gastric Cancer – Are They Steps Ahead?" European Journal of Cancer 47 (September 2011): S74. http://dx.doi.org/10.1016/s0959-8049(11)70543-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kebede, Tsigereda, Ingunn Marie S. Engebretsen, Selamawit Bilal, and Bernt Lindtjørn. "Dietary Diversity and Nutritional Status of Children Aged 6 to 24 Months in Rural Sidama, Southern Ethiopia." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 533. http://dx.doi.org/10.1093/cdn/nzaa046_033.

Full text

Abstract:

Abstract Objectives To describe dietary diversity score (DDS) of young children and to assess the association of DDS with stunting and anaemia (defined as haemoglobin level <11 mg/dl) in rural Southern Ethiopia. Methods A cross-sectional household study was done in rural Dale Woreda, Southern Ethiopia from August to October 2018 among 804 caregiver-child (aged 6–24 months) pairs. Dietary history, anthropometric measurements and haemoglobin levels using HemoCue HB 301 portable machines were captured. Child DDS was assessed in a structured 24-hour recall on specific common food items with relevance for the standard 7-food groups DDS (WHO). Stunting was defined as length-for-age Z-score less than 2 SD from the population mean according to the WHO Child Growth Standards. Results from adjusted logistic regression models are presented for stunting and anaemia as the dependent variables (using SPSS software). Results Children received only foods from 1 and 2 food groups were 5.0% (40/804) and 14.9% (120/804), respectively. There was 43.9% (353/804) of children who had low DDS (received foods from less than four out of seven food groups) during 24 hours prior to the interviews. The prevalence of stunting was 47.8% (384/804) and 45.6% (367/804) for anaemia. The odds ratio for stunting was 2 and 3 times higher among children who did not receive legumes and flesh foods compared to those who received it: aOR = 2.0, 95% CI 1.2; 3.3 and 2.9, 95% CI 1.6; 5.5, respectively. Children who did not receive cereals and legumes had similarly increased risk of having haemoglobin level below 11 mg/dl compared to those who received it: aOR = 2.6, 95% CI 1.0; 6.8 and 2.8, 95% CI 1.7; 4.7, respectively. Conclusions In Dale Woreda, Southern Ethiopia, the prevalences of stunting and anaemia were high and children had low dietary diversity. Dietary diversity among young children must be considered in Ethiopian strategies promoting the health of children. Funding Sources NORAD (Norwegian Agency for development co-operation), through the NORHED (Norwegian program for capacity development in higher education and research for development) program.

APA, Harvard, Vancouver, ISO, and other styles

17

INOUE-NAGATA, ALICE K., M. ESTHER N. FONSECA, TATIANA O. T. A. LOBO, ANTÔNIO C. DE ÁVILA, and DAMARES C. MONTE. "Analysis of the nucleotide sequence of the coat protein and 3'-untranslated region of two Brazilian Potato virus Y isolates." Fitopatologia Brasileira 26, no. 1 (March 2001): 45–52. http://dx.doi.org/10.1590/s0100-41582001000100008.

Full text

Abstract:

Two Brazilian Potato virus Y (PVY) isolates were biologically characterized as necrotic (PVY-NBR) and common (PVY-OBR) based upon symptoms on test plants. Additional characterization was performed by sequencing a cDNA corresponding to the 3' terminal region of the viral genome. The sequence consisted of 195 nucleotides (nt) coding part of the nuclear inclusion body b (NIb) gene, 804 nt of the coat protein (CP) gene, and 328 nt (PVY-OBR) or 326 nt (PVY-NBR) of the 3'-untranslated region (UTR). Translation of the sequence resulted in one single open reading frame with part of the NIb and a CP of 267 amino acids. The two isolates shared 95.1% similarity in the CP amino acid sequence. The CP and the 3'-UTR sequence of the Brazilian isolates were compared to those of other PVY isolates previously reported and unrooted phylogenetic trees were constructed. The trees revealed a separation of two distinct clusters, one comprising most of the common strains and the other comprising the necrotic strains. PVY-OBR was clustered in the common group and PVY-NBR in the necrotic one.

APA, Harvard, Vancouver, ISO, and other styles

18

Zhang, Xiao Zhen, Jian Er Zhou, Yong Qing Wang, and Yu Hua Jiang. "Micro-Tubular Solid Oxide Fuel Cell with Graded Anode and Cobalt-Free SrFe_0.9Sb_0.1O _3−δ Perovskite Cathode." Advanced Materials Research 311-313 (August 2011): 2415–19. http://dx.doi.org/10.4028/www.scientific.net/amr.311-313.2415.

Full text

Abstract:

Micro-tubular solid oxide fuel cell (SOFC) has been fabricated with NiO-YSZ hollow fiber as anode support and SrFe0.9Sb0.1O3−δ-Sm0.2Ce0.8O1.9(SFSb-SDC) composite cathode. The NiO-YSZ hollow fiber anode was prepared by the immersion-induced phase inversion technique and shows a special asymmetrical structure with long and large finger-like porous structure near the lumen side of the hollow fiber. A thin and dense electrolyte membrane (about 12μm) was deposited on the anode by a vacuum-assisted dip-coating process. The performance of the as-prepared micro-tubular SOFC was tested at 600-800°C with humidified H2 as fuel and ambient air as the oxidant. The peak power densities of 462.8, 336.6 and 201.4 mWcm-2can be obtained at 800, 700 and 600°C, respectively. The experimental results indicate that the cobalt-free SFSb was a promising cathode material and the prepared YSZ-based micro-tubular SOFC has potential applications as power sources for portable devices.

APA, Harvard, Vancouver, ISO, and other styles

19

Luca', R., M. Averna, M. Vecchi, F. Zalfa, G. LaFata, P. Neven, G. Evans, P. Carmeliet, M. Mazzone, and C. Bagni. "328 Role of the Fragile X Mental Retardation Protein in Tumor Progression and Metastasis Formation." European Journal of Cancer 48 (July 2012): S80. http://dx.doi.org/10.1016/s0959-8049(12)71018-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Meetze, K., K. Connolly, B. Feng, W. Rideout, J. Gyuris, and M. Han. "301 Antitumor Activity of Ficlatuzumab in Combination with Tivozanib On Primary Human Renal Cell Carcinoma Xenografts." European Journal of Cancer 48 (November 2012): 92. http://dx.doi.org/10.1016/s0959-8049(12)72099-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sunohara, M., M. Kawakami, K. Watanabe, S. Morita, H. Kage, Y. Amano, M. Fukayama, T. Nagase, N. Ohishi, and D. Takai. "311 Vandetanib Can Overcome the Acquired Resistance to Gefitinib Due to RET Overexpression in Lung Cancer." European Journal of Cancer 48 (November 2012): 95. http://dx.doi.org/10.1016/s0959-8049(12)72109-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Latagliata, Roberto, Michele Cedrone, Nicoletta Villivà, Massimo Breccia, Barbara Anaclerico, Paola Volpicelli, Antonella Ferretti, et al. "Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features." Blood 116, no. 21 (November 19, 2010): 3077. http://dx.doi.org/10.1182/blood.v116.21.3077.3077.

Full text

Abstract:

Abstract Abstract 3077 Hydroxyurea (HU) is still the cornerstone in the cytoreductive treatment of Myeloproliferative Neoplasms (MPN); however, skin toxicity has been reported as a limiting toxicity during HU treatment in many case reports. To evaluate the real incidence and the clinical features of such complication, among 942 patients with MPN consecutively diagnosed at 3 Centers in Rome, we revised 587 patients (M/F 263/324, median age 64.2 years, IR 53.7 – 72.7) who received HU treatment during the course of disease. There were 304 patients with Essential Thrombocythemia (ET), 202 with Polycythemia Vera (PV), 68 with Primary Myelofibrosis (PMF) and 13 with unclassifiable Chronic Myeloproliferative Disorders (CMPD-u); 496 patients (84.5%) received HU as 1st line treatment while 91 (15.5%) as 2nd or 3rd line treatment. On the whole, 50 patients (8.5%) had a skin toxicity during HU treatment, after a median period from HU start of 32.1 months (IR 10.5 – 74.6) and a mean HU dosage of 1085 mg (+/&− 390 mg); as to the different types of toxicity, 31 patients (62%) had a painful ulcerative skin toxicity (UST) that in 25/31 was located in the perimalleolar area, 9 patients (18%) had oral aphthous ulcers and 10 patients (20%) a non ulcerative skin toxicity (NUST) with erythema and skin infiltration (diffuse in 2 patients, localized to the head or to the extremities in 5 and 3 patients, respectively). Among these different types of skin toxicity there was no difference as to mean HU dosage; however, oral aphthous ulcers were an early toxicity (median time from HU start 1.9 months, IR 1.6 – 2.7) while UST and NUST were late complications (median time from HU start 35.1 months, IR 22.9 – 81.7, and 36.1 months, IR 17.0 – 64.5, respectively). When the skin toxicity occurred, HU treatment was continued at the same dosage in 5 patients (10%), was reduced in 12 patients (24%) and temporarily interrupted in 7 patients (14%); the remaining 26 patients (52%) needed a permanent drug discontinuation. After a median period of 4.3 months (IR 2.4 – 9.0) from the onset of the skin toxicity, 38 patients (76%) had a complete resolution and 8 patients (24%) an improvement without complete resolution; oral aphthous ulcers and NUST had a shorter median time of resolution compared to UST (1.8 months, IR 0.7 – 6.6, and 3.1 months, IR 3.0 – 8.4, versus 6.0 months, IR 3.1 – 16.5, respectively). In conclusion, skin toxicity during HU treatment is more common than expected, with about 9% of incidence and can have different clinical features; moreover, it often need a permanent drug discontinuation and in about 25% of patients there is only a partial resolution. Thus, further studies are warranted to highlight pathogenesis, which could be different in the various types of toxicity, and individual predisposing factors. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

23

Heusschen, Laura, Ineke Krabbendam, Jessika M. van der Velde, Laura N. Deden, Edo O. Aarts, Ashley E. R. Merién, Marloes Emous, Gysèle S. Bleumink, Helen L. Lutgers, and Eric J. Hazebroek. "A Matter of Timing—Pregnancy After Bariatric Surgery." Obesity Surgery 31, no. 5 (January 11, 2021): 2072–79. http://dx.doi.org/10.1007/s11695-020-05219-3.

Full text

Abstract:

Abstract Purpose Current guidelines recommend to avoid pregnancy for 12–24 months after bariatric surgery because of active weight loss and an increased risk of nutritional deficiencies. However, high-quality evidence is lacking, and only a few studies included data on gestational weight gain. We therefore evaluated pregnancy and neonatal outcomes by both surgery-to-conception interval and gestational weight gain. Materials and Methods A multicenter retrospective analysis of 196 singleton pregnancies following Roux-en-Y gastric bypass, sleeve gastrectomy, and one anastomosis gastric bypass was conducted. Pregnancies were divided into the early group (≤ 12 months), the middle group (12–24 months), and the late group (> 24 months) according to the surgery-to-conception interval. Gestational weight gain was classified as inadequate, adequate, or excessive according to the National Academy of Medicine recommendations. Results Pregnancy in the early group (23.5%) was associated with lower gestational age at delivery (267.1 ± 19.9 days vs 272.7 ± 9.2 and 273.1 ± 13.5 days, P = 0.029), lower gestational weight gain (− 0.9 ± 11.0 kg vs + 10.2 ± 5.6 and + 10.0 ± 6.4 kg, P < 0.001), and lower neonatal birth weight (2979 ± 470 g vs 3161 ± 481 and 3211 ± 465 g, P = 0.008) than pregnancy in the middle and late group. Inadequate gestational weight gain (40.6%) was associated with lower gestational age at delivery (266.5 ± 20.2 days vs 273.8 ± 8.4 days, P = 0.002) and lower neonatal birth weight (3061 ± 511 g vs 3217 ± 479 g, P = 0.053) compared to adequate weight gain. Preterm births were also more frequently observed in this group (15.9% vs 6.0%, P = 0.037). Conclusion Our findings support the recommendation to avoid pregnancy for 12 months after bariatric surgery. Specific attention is needed on achieving adequate gestational weight gain.

APA, Harvard, Vancouver, ISO, and other styles

24

Yang, Yong Shun, Ke Feng, and Wen Xia Zhao. "Fabrication and Properties of Al₂O₃Short Fiber Reinforced Aluminium Matrix Composites." Advanced Materials Research 328-330 (September 2011): 1277–80. http://dx.doi.org/10.4028/www.scientific.net/amr.328-330.1277.

Full text

Abstract:

The Poly-crystal alumina short fiber reinforcing 2024 matrix composites was produced by the gas pressure infiltration, and a new apparatus has been developed for the infiltration of MMCs by the gas pressure infiltration technique. The reasonable sintering parameter for the preform were determined.The preform was heated at 450°C to remove the organic binder and pore-forming material, and then heated at 1050°C for 2.5h to obtain the comprehensive properties.Scanning electron microscope was used to observe the tensile fracture of Aluminum matrix composites, and the fracture feature of composites produced in different temperature was analyzed. The melting temperature of 2024Al was 800°C and holding time was 20mins; the infiltration gas pressure was 0.5Mpa and holding time was 20s.And then interface reaction is appropriate between the fiber and matrix ,a good performance of composites was produced.

APA, Harvard, Vancouver, ISO, and other styles

25

Hehlmann, Rüdiger, Susanne Jung-Munkwitz, Michael Lauseker, Martin C. Müller, Armin Leitner, Nadine Pletsch, Ulrike Proetel, et al. "Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV." Blood 116, no. 21 (November 19, 2010): 357. http://dx.doi.org/10.1182/blood.v116.21.357.357.

Full text

Abstract:

Abstract Abstract 357 Treatment of CML with imatinib of 400 mg can be unsatisfactory. Treatment optimization is warranted. The German CML-Study group has therefore conducted a randomized study comparing imatinib 800 mg vs 400 mg vs 400 mg + IFN. A significantly faster achievement of MMR at 12 months has been observed with imatinib 800 mg in a tolerability adapted manner and MMR by 12 months has been found to translate into better overall survival. Since stable CMR has been associated with durable off-treatment remissions we sought to analyse the impact of tolerability-adapted imatinib 800 mg on CMR and survival. Standardized determinations of molecular response and evaluation of its impact on outcome are goals of CML-Study IV. CMR4 is defined as a BCR-ABL/ABL ratio of <0,01 on the International Scale. From July 2002 – April 30, 2009 1022 newly diagnosed patients with CML in chronic phase were randomized, 1012 were evaluable (338 with imatinib 800 mg, 324 with imatinib 400 mg, 350 with imatinib plus IFN). Median observation time was 40 months. The median average daily imatinib doses were 628 mg in the 800 mg arm and 400 mg in the 400 mg based arms. The actual median daily doses in the 800 mg arm per 3-months periods were: 555 mg, 737 mg, 613 mg, 600 mg, and 600 mg thereafter, reflecting the run–in period with imatinib 400 mg for 6 weeks in the first period and the adaptation to tolerability from the third 3-months period onwards. Median daily imatinib doses in the 400 mg arms were 400 mg throughout. Adaptation of imatinib dose in the 800 mg arm according to tolerability is reflected by similar higher-grade adverse events rates (WHO grades 3 and 4) with all treatments. Significantly higher remission rates were achieved with imatinib 800 mg by 12 months. The cumulative incidences of CCR by 12 months were 63% [95%CI:56.4-67.9] with imatinib 800 mg vs 50% [95%CI:43.0-54.5] with the two 400 mg arms. The cumulative incidences of MMR by 12 months were 54.8% [95%CI:48.7-59.7] with imatinib 800 mg vs 30.8% [95%CI:26.6-36.1] with imatinib 400 mg vs 34.7% [95%CI:29.0-39.2] with imatinib + IFN. The cumulative incidences of CMR4 compared with the MMR incidences over the first 36 months are shown in Table 1. Imatinib 800 mg shows superior CMR4 rates over the entire 36 months period, CMR4 is reached significantly faster with imatinib 800 mg as compared to the 400 mg arms. The CMR4 rates reach 56.8% by 36 months [95%CI:49.4-63.5] as compared to 45.5% with imatinib 400 mg [95%CI:38.7-51.0] and 40.5% with imatinib plus IFN [95%CI:34.6-46.3]. Most patients have stable CMR4 over the entire period. Time after start of treat-ment (months) Cumulative incidences MMR(%) CMR4 (%) IM400 n=306 D IM800 n=328 D IM400 +IFN n=336 IM400 n=306 D IM800 n=328 D IM400 +IFN n=336 6 8.6 9.5 18.1 9.7 8.4 3 0.7 3.7 1.3 2.4 12 30.8 24.0 54.8 20.1 34.7 7.5 12.3 19.8 7.4 12.4 18 50.3 18.1 68.4 14.3 54.1 21.2 12.2 33.4 9.8 23.6 24 63 13.0 76.0 13.2 62.8 30.7 12.3 43 13 30.0 36 79.3 2.3 81.6 10.9 70.7 45.5 11.3 56.8 16.3 40.5 In summary, superior CMR4 rates are achieved with high-dose imatinib adapted to good tolerability, and more patients in the tolerability-adapted 800 mg arm have stable CMR4 qualifying for treatment discontinuation as compared to the 400 mg based arms. With improved application imatinib remains first choice for early CML. Disclosures: Koschmieder: Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees. Schnittger:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. German CML-Study Group:Deutsche Krebshilfe: Research Funding; Novartis: Research Funding; Roche: Research Funding; BMBF: Research Funding; Essex: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

26

Buller, Harry R. "Efficacy and Safety of Fondaparinux (ARIXTRA®) in the Initial Treatment of Venous Thromboembolism in Obese Patients." Blood 104, no. 11 (November 16, 2004): 706. http://dx.doi.org/10.1182/blood.v104.11.706.706.

Full text

Abstract:

Abstract Background: The MATISSE trials demonstrated that once-daily subcutaneous fondaparinux, a synthetic selective factor Xa inhibitor, was at least as effective and as safe as standard therapies in the initial treatment of deep-vein thrombosis (DVT) or pulmonary embolism (PE). Since obesity is a risk factor for venous thromboembolism (VTE), we analyzed the MATISSE data from the subpopulation of obese patients (body-mass index, BMI ≥30 kg/m2). Methods: Fondaparinux was administered at a once-daily subcutaneous dose of 7.5 mg (5.0 mg and 10.0 mg in patients <50 kg and >100 kg, respectively). In the MATISSE-DVT trial, fondaparinux was compared with twice-daily subcutaneous enoxaparin (1 mg/kg) in patients with DVT. In the MATISSE-PE trial, it was compared with adjusted-dose intravenous unfractionated heparin (UFH) in patients with PE. All drugs were given for at least 5 days and until anticoagulation with oral anticoagulants was therapeutic. The primary efficacy and safety outcomes were recurrent VTE during 3 months’ follow-up and major bleeding (MB) and death during the initial treatment period. Results: The percentage of obese patients was 26.3% in MATISSE-DVT and 28.7% in MATISSE-PE (Tables). In both MATISSE-DVT and -PE, efficacy and safety data from obese patients were similar to those from non-obese patients (BMI <30kg/m2). The rates of recurrent VTE and MB in obese patients were not significantly different between fondaparinux and either enoxaparin (MATISSE-DVT) or UFH (MATISSE-PE). Conclusion: Once-daily fondaparinux is at least as effective and as safe as standard therapies in the initial treatment of DVT or PE in obese patients. MATISSE DVT BMI<30 kg/m2 BMI≥30 kg/m2 Enoxaparin Fondaparinux Enoxaparin Fondaparinux *As treated patients n 791 803 300 280 VTE, n/N 35/791 (4.4%) 31/803 (3.9%) 10/300 (3.3%) 10/280 (3.6%) MB*, n/N 10/788 (1.3%) 12/798 (1.5%) 3/297 (1.0%) 0/279 (0%) MATISSE PE BMI<30 kg/m2 BMI≥30 kg/m2 UFH Fondaparinux UFH Fondaparinux *As Treated Patients n 760 757 322 314 VTE, n/N 35/760 (4.6%) 30/757 (4.0%) 20/322 (6.2%) 12/314 (3.8%) MB*, n/N 8/752 (1.1%) 11/751 (1.5%) 4/314 (1.3%) 2/311 (0.6%)

APA, Harvard, Vancouver, ISO, and other styles

27

Stępień, K., R. P. Ostrowski, E. B. Pucko, Z. Kazimierczuk, and E. Matyja. "322 Impact of oxygen level changes on proliferation and viability of glioma cell lines treated with selected pentabromobenzylisothiourea." European Journal of Cancer 51 (September 2015): S62. http://dx.doi.org/10.1016/s0959-8049(16)30187-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kaesmacher, Johannes, Nuran Abdullayev, Basel Maamari, Tomas Dobrocky, Jan Vynckier, Eike I. Piechowiak, Raoul Pop, et al. "Safety and Angiographic Efficacy of Intra-Arterial Fibrinolytics as Adjunct to Mechanical Thrombectomy: Results from the INFINITY Registry." Journal of Stroke 23, no. 1 (January 31, 2021): 91–102. http://dx.doi.org/10.5853/jos.2020.01788.

Full text

Abstract:

Background and Purpose Data on safety and efficacy of intra-arterial (IA) fibrinolytics as adjunct to mechanical thrombectomy (MT) are sparse.Methods INtra-arterial FIbriNolytics In ThrombectomY (INFINITY) is a retrospective multi-center observational registry of consecutive patients with anterior circulation large-vessel occlusion ischemic stroke treated with MT and adjunctive administration of IA fibrinolytics (alteplase [tissue plasminogen activator, tPA] or urokinase [UK]) at 10 European centers. Primary outcome was the occurrence of symptomatic intracranial hemorrhage (sICH) according to the European Cooperative Acute Stroke Study II definition. Secondary outcomes were mortality and modified Rankin Scale (mRS) scores at 3 months.Results Of 5,612 patients screened, 311 (median age, 74 years; 44.1% female) received additional IA after or during MT (194 MT+IA tPA, 117 MT+IA UK). IA fibrinolytics were mostly administered for rescue of thrombolysis in cerebral infarction (TICI) 0-2b after MT (80.4%, 250/311). sICH occurred in 27 of 308 patients (8.8%), with an increased risk in patients with initial TICI0/1 (adjusted odds ratio [aOR], 2.3; 95% confidence interval [CI], 1.1 to 5.0 per TICI grade decrease) or in those with intracranial internal carotid artery occlusions (aOR, 3.7; 95% CI, 1.2 to 12.5). In patients with attempted rescue of TICI0-2b and available angiographic follow-up, 116 of 228 patients (50.9%) showed any angiographic reperfusion improvement after IA fibrinolytics, which was associated with mRS ≤2 (aOR, 3.1; 95% CI, 1.4 to 6.9).Conclusions Administration of IA fibrinolytics as adjunct to MT is performed rarely, but can improve reperfusion, which is associated with better outcomes. Despite a selection bias, an increased risk of sICH seems possible, which underlines the importance of careful patient selection.

APA, Harvard, Vancouver, ISO, and other styles

29

Martin, W. Davis, and G. A. Herzog. "LIFE HISTORY STUDIES OF THE TOBACCO FLEA BEETLE, EPITRIX HIRTIPENNIS (MELSHEIMER) (COLEOPTERA: CHRYSOMELIDAE)." Journal of Entomological Science 22, no. 3 (July 1, 1987): 237–44. http://dx.doi.org/10.18474/0749-8004-22.3.237.

Full text

Abstract:

The life history of the tobacco flea beetle, Epitrix hirtipennis (Melsheimer) (= Epitrix parvula Fab.) was studied under the controlled conditions of 27 ± 2.8°C, 80 ± 6% and a 14L:10D photophase. Eggs matured in ca. 4 days, the larval stage, including 3 instars, developed in 13 days, prepupal development took 3 days and the pupal stage lasted approximately 5 days. There was a 24 day interval between oviposition and adult emergence. Females laid 3.1 eggs/day with a 13 day period between adult emergence and first oviposition. The mean number of total eggs/female was 138.6 ± 14.7. Female oviposition continued until a few days before death and adult longevity was approximately 70 days. A visual means of distinguishing between male and female beetles was also developed.

APA, Harvard, Vancouver, ISO, and other styles

30

Srinivasan, Nitin, Jayasree Chandramathi, Aswin S. Prabhu, and Sasidharan Ponthenkandath. "Vitamin D deficiency and morbidity among preterm infants in a developing country." International Journal of Contemporary Pediatrics 4, no. 2 (February 22, 2017): 499. http://dx.doi.org/10.18203/2349-3291.ijcp20170697.

Full text

Abstract:

Background: The association of serum vitamin D levels to clinical outcome in VLBW infants has not been studied. Our objective was to measure the cord blood levels, and the dose response for two doses of vitamin D in preterm infants and correlate the relationship of vitamin D levels to the clinical outcome.Methods: We prospectively obtained cord blood levels in 80 preterm infants under 34 weeks gestation (mean gestation age 29±2 weeks and BW: 1210±350 gms). Infants were supplemented with 400 IU or 800-1000 IU vitamin D daily. Serun vitamin D levels were obtained at 2 - 3 weeks after supplementation and levels were correlated to clinical outcome. Results: The mean cord blood vitamin D level was 12±8.5 ng/ml. Babies who developed sepsis and compared to those who did not develop these morbidities, ROP had vitamin D levels: 13.5±6 (ng/ml) versus 30.5±10 (ng/ml) (p < 0.01) and 15.7±11 (ng/ml) versus 34±18 (ng/ml) (p <0.03) respectively. Supplementation with 400 IU vitamin D resulted in levels of 17±8.6 (ng/ml) and infants given 800-1000 IU vitamin D had levels 46±17(ng/ml) (p <0.001).Conclusions: These data suggest that cord blood vitamin D levels are low in preterm infants and 800-1000 IU vitamin D supplementation is advisable to achieve levels >30 ng/ml. Infants with low levels of vitamin D have higher incidence of sepsis, and ROP.

APA, Harvard, Vancouver, ISO, and other styles

31

Panyushkina, Irina, Igor Sljusarenko, Nikolay Bikov, and Eugene Bogdanov. "Floating Larch Tree-Ring Chronologies from Archaeological Timbers in the Russian Altai Between about 800 BC and AD 800." Radiocarbon 49, no. 2 (2007): 693–702. http://dx.doi.org/10.1017/s0033822200042582.

Full text

Abstract:

We obtained over 200 archaeological wood specimens from the southeastern part of the Altai Mountains (Russia) to establish accurate calendar dates of the timbers using both radiocarbon and tree-ring analyses. Most timbers came from small and elite tombs of the Pazyryk culture (Siberian Scythians of the Iron Age period). Timbers from Hun-Sarmatian and Turk times (1st millennium AD) were studied for the first time. Three floating tree-ring width chronologies of larch (Larix sibirica) with lengths of 486 yr to 144 yr were developed from the tree-ring data. Tree rings of the composite 486-yr chronology of the Pazyryk culture represent the regional scale of Altai tree-ring width variability between about 720–240 BC. The composite chronology dates the earliest construction of Pazyryk culture tombs to ∼320 BC (ordinary tombs) and the latest ones at 240 BC (Pazyryk noble tomb #5). The composite chronology might be used for tree-ring dating wood from Scythian tombs in the region. It will also help confirm the precision of 14C dating of the Scythian tombs around the Hallstatt plateau of 14C calibration curves. We developed a 110-yr decadal 14C sequence from the Kurayka site that dates Kok-Pash culture timbers back to cal AD 240 (Hun-Sarmatian period). 14C dates of wooden poles from 3 sites of Turk stone enclosures suggested wood cutting dates between cal AD 470 and 830. The results demonstrate that crossdating tree rings along with 14C dating of crossdated rings provide the most reliable and highest precision dates for these archaeological sites.

APA, Harvard, Vancouver, ISO, and other styles

32

Chadwick, Owen. "Theologische Realenzyklopädie, XIII: Gesellschaft/Gesellschaft und Christentum VI–Gottesbeweise. Edited by Gerhard Müller. Pp. 804 + 31 ills. Berlin–New York: Walter de Gruyter, 1984. DM 320. 3 11 008581 X." Journal of Ecclesiastical History 41, no. 1 (January 1990): 74–76. http://dx.doi.org/10.1017/s0022046900073437.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

LOO, B. H., M. T. EMERSON, N. P. WANG, D. H. BURNS, and C. Y. HUANG. "A COMPARATIVE STUDY OF RAMAN SPECTRA AND SUPERCONDUCTING CHARACTERISTICS OF 90 K SUPERCONDUCTORS." Modern Physics Letters B 05, no. 21 (September 10, 1991): 1415–29. http://dx.doi.org/10.1142/s0217984991001714.

Full text

Abstract:

The Raman spectra and superconducting characteristics of ReBa 2 Cu 3 O 7−x where Re = Y, Nd, Sm, Eu, Gd, Dy and Ho have been studied. We have unambiguously established that the 320- and 500- cm −1 modes, consistently appearing in the 200–800 cm −1 region of the Raman spectra of good quality superconducting Re123 samples with large diamagnetic shielding values, are intrinsically belonged to the Re123 orthorhombic superconducting phase.

APA, Harvard, Vancouver, ISO, and other styles

34

Herlambang, Yusuf Dewantoro, Budhi Prasetiyo, Supriyo Supriyo, Wahyono Wahyono, and Teguh Harijono Mulud. "MODEL TURBIN ANGIN AIRFOIL NACA 4418 TERHADAP VARIASI BUKAAN SUDUT SUDU PADA KECEPATAN ANGIN BERBEDA." JURNAL INTEGRASI 11, no. 2 (October 17, 2019): 97–102. http://dx.doi.org/10.30871/ji.v11i2.1659.

Full text

Abstract:

Penelitian ini mengkaji Turbin Angin Sumbu Vertikal (Vertical Axis Wind Turbine) Aerofoil NACA 4418 yang memiliki diameter rotor 560 mm, panjang sudu 800 mm, jumlah sudu 3 buah, serta bahan sudu terbuat dari fiberglass. Selanjutnya menganalis karakteristik turbin angin rotor vertikal 3-sudu tersebut pada kecepatan angin berbeda 5 m/s, 6 m/s, 7 m/s, 8 m/s, dan 9 m/s dengan 5 buah model turbin angin dengan bukaan sudut sudu (blade pitch angle) bervariasi yaitu 00, 100, 200, 300, dan 400. Hasil pengujian turbin angin diperoleh rasio kecepatan sudu (Tip Speed Ratio) yang optimum sebesar 1,7 pada sudut sudu 100 dengan putaran turbin 321 rpm dan kecepatan angin 5,42 m/s. Daya mekanik optimum yang diperoleh adalah 19,4 W pada bukaan sudut sudu sebesar 200 dengan putaran turbin 381 serta kecepatan angin 6,4 m/s. Turbin menghasilkan koesifien daya (Coefficient of Power) optimum yang dihasilkan sebesar 0,202 dengan bukaan sudut sudu sebesar 100 dan putaran turbin 198 rpm, dan daya mekanik yang dihasilkan 8,5 Watt pada variabel pengujian kecepatan sebesar 5,42 m/s.

APA, Harvard, Vancouver, ISO, and other styles

35

McCue, Morgan, Jamie L. Reichert, and Thomas D. Crenshaw. "Impact of dietary vitamin D3 supplements in nursery diets on subsequent growth and bone responses of pigs during an immune challenge." Journal of Animal Science 97, no. 12 (November 8, 2019): 4895–903. http://dx.doi.org/10.1093/jas/skz347.

Full text

Abstract:

Abstract Limited evidence is available to validate beneficial responses from extra nutrient supplements for mediation of growth suppression that results from immune challenges. Extrarenal roles of vitamin D metabolites in immune function implicate vitamin D3 supplements as a nutrient for potential beneficial effects. The current objective was to assess growth and bone ash responses to dietary vitamin D3 (D) supplements for growing pigs undergoing an immune challenge. At weaning, 216 crossbred pigs (4 pigs/pen, 6 pens/treatment) were randomly allotted within sex and weight blocks to 1 of the 9 treatments. Treatments included D supplements (0, 100, or 800 IU/kg) in a factorial arrangement with 3 vaccine (V) protocols; no injection (0 × V), a single 2 mL injection of a Lawsonia intracellularis vaccine at day 14 (1 × V), or 2 mL injections of the same vaccine at days 0 and 7 (2 × V). An adjustment diet with no supplemental D was fed for 1 wk, then assigned D diets for 2 wk (P2). After P2, all pigs were phase-fed standard diets (D = 280 IU/kg) to assess subsequent growth to 115 kg. No differences due to D supplements or vaccination protocol were detected in ADG (0.233 ± 0.021 kg/d) or GF (0.642 ± 0.028 kg/d) over the 21-d nursery trial; however, ADFI was lower (P < 0.10) in pigs fed D levels of 0 vs. 100 and 800 (0.340 vs. 0.375, 0.372 ± 0.027 kg/d). Bone mineral content (g) from whole-body dual energy X-ray absorptiometry scans at 9 wk (n = 4 pigs/treatment) was lower in pigs fed 0 vs. 100 and 800 IU of D (287 vs. 325, 323 ± 34.1 g/pig). Growth from nursery to 115 kg was lower (P < 0.01) in pigs fed D levels of 0 vs.100 and 800 (0.828 vs. 0.876, 0.889 ± 0.021 kg/d). At market, approximately two-thirds of pigs showed positive L. intracellularis serology titers regardless of treatment. Limited evidence for D-mediation of an immune challenge using the vaccination protocols may be a consequence of limited vaccine effects on growth in the nursery and seroconversion of most pigs to L. intracellularis by market.

APA, Harvard, Vancouver, ISO, and other styles

36

Brandstätter, Birgit, Benedikt Auer, Hannes Klingler, and Sabine Scherbaum. "High-Accuracy Pick-and-Place of Multiple Dies in Parallel Assisted by Capillary Self-Alignment." International Symposium on Microelectronics 2021, no. 1 (October 1, 2021): 000074–79. http://dx.doi.org/10.4071/1085-8024-2021.1.000074.

Full text

Abstract:

Abstract Self-assembly of components driven by liquid surface tension is an attractive complement and even alternative to traditional high-accuracy pick-and-place as it offers high accuracy despite inaccurate robotic part placement. While capillary self-alignment through liquid solder is the standard technology for flip-chip processes, this work presents self-alignment of dies on wetted receptors on a temporary carrier: Low-viscosity liquid is jetted on each receptor where the liquid is contained through generation of hydrophilic and hydrophobic sections on the temporary carrier by plasma treatment. Deterministic die feeding by low-accuracy pick-and-place is conducted for single dies, as well as for batches of three dies and nine dies optimizing the equipment for best throughput to achieve both high accuracy and high productivity. The industry-ready and fully automated chip-to-wafer pick-and-place process is implemented into a fan-out wafer-level packaging production flow proving that self-alignment is capable of easing the stringent requirement for robotic alignment capability for pick-and-place systems in fan-out packaging for the single die-level step in this production chain. The self-alignment process is optimized, and failure modes such as poor liquid confinement, surface contamination, or excess force are identified and eliminated. Post-bond accuracy of <3 μm @ 3 σ at each point of the die is reached for dies of 3.1 mm x 3.1 mm in size. Using parallel die handling, high speeds of around 10 000 units per hour are made possible.

APA, Harvard, Vancouver, ISO, and other styles

37

Iwata, Ikuru, Akio K. Inoue, Genoveva Micheva, Yuichi Matsuda, and Toru Yamada. "Subaru narrow-band imaging search for Lyman continuum from galaxies at z > 3 in the GOODS-N field." Monthly Notices of the Royal Astronomical Society 488, no. 4 (July 30, 2019): 5671–89. http://dx.doi.org/10.1093/mnras/stz2081.

Full text

Abstract:

Abstract We report results of a search for galaxies at z > 3 with Lyman continuum (LyC) emission using a narrow-band filter NB359 with Subaru/Suprime-Cam in an ∼800 arcmin2 blank field around the GOODS-N. We use 103 star-forming galaxies (SFGs) and 8 active galactic nuclei (AGNs) with spectroscopic redshifts in a range between 3.06 and 3.5 and 157 photometrically selected z = 3.1 Lyman α emitter (LAE) candidates as the targets. After removing galaxies spectroscopically confirmed to be contaminated by foreground sources, we found two SFGs and one AGN as candidate LyC-emitting sources among the targets with spectroscopic redshifts. Among LAE candidates, five sources are detected in the NB359 image, and three among them may be contaminated by foreground sources. We compare the sample galaxies in the GOODS-N with those in the SSA22, where a prominent protocluster at z = 3.1 is known and an LyC search using the same NB359 filter has been made. The frequency of galaxies with LyC leakage in the SSA22 field may be about two times higher than that of galaxies in the GOODS-N with the sample ultraviolet (UV) magnitude range, although the numbers of LyC detections in these fields are too small to make a statistically significant conclusion. By combining the sample galaxies in these fields, we place the 3σ upper limits of the observed LyC-to-UV flux density ratio and LyC escape fraction for galaxies at z = 3.1 with absolute UV magnitude MUV < −18.8 as (fLyC/fUV)obs < 0.036 and $f_\mathrm{esc}^\mathrm{abs}\,\lt\, 8$ per cent, respectively.

APA, Harvard, Vancouver, ISO, and other styles

38

FANG, GUO-YONG, LI-NA XU, XIN-GEN HU, XIN-HUA LI, HE-MING XIAO, XUE-HAI JU, and XUE-DONG GONG. "DENSITY FUNCTIONAL THEORY STUDY OF THE INTERACTION BETWEEN 3-NITRO-1,2,4-TRIAZOLE-5-ONE AND WATER." Journal of Theoretical and Computational Chemistry 04, no. 03 (September 2005): 849–56. http://dx.doi.org/10.1142/s021963360500188x.

Full text

Abstract:

Three fully optimized geometries of 3-nitro-1,2,4-triazol-5-one (NTO)-H2O complexes have been obtained with density function theory (DFT) method at the B3LYP/6-311++G** level. The intermolecular interaction energy is calculated with zero point energy (ZPE) correction and basis set superposition error (BSSE) correction. The greatest corrected intermolecular interaction of the NTO–H2O complexes is -30.14 KJ/mol. Electrons in complex systems transfer from H2O to NTO . The strong hydrogen bonds contribute to the interaction energies dominantly. Natural bond orbital (NBO) analysis is performed to reveal the origin of the interaction. Based on the vibrational analysis, the changes of thermodynamic properties from the monomer to complexes with the temperature ranging from 200 K to 800 K have been obtained using the statistical thermodynamic method. It is found that three NTO –water complexes can be produced spontaneously from NTO and H2O at lower temperature.

APA, Harvard, Vancouver, ISO, and other styles

39

Upton, Steve J., Paul S. Freed, Deborah A. Burdick, and Chris T. McAllister. "Seven new species of coccidia (Apicomplexa: Eimeriorina) from reptiles in Madagascar." Canadian Journal of Zoology 68, no. 11 (November 1, 1990): 2368–75. http://dx.doi.org/10.1139/z90-329.

Full text

Abstract:

Seven new species of coccidia (Apicomplexa: Eimeriorina) are described from reptiles in Madagascar. Oocysts of Caryospora barnardae sp.nov. from 1/1 Liopholidophis stumpffi (Boettger, 1881) were small and spherical, measuring 13.7 (11.2–15.2) μm. Oocysts of C. brygooi sp.nov. from 1/4 Madagascarophis colubrinus (Schlegel, 1837) were spherical or subspherical, 20.2 × 19.7 (18.6–21.6 × 17.6–21.2) μm. Oocysts of C. madagascariensis sp.nov. from 3/4 M. colubrinus (type host) and 1/6 Mimophis mahfalensis (Grandidier, 1867) were large, 26.2 × 24.2 (21.6–30.0 × 21.0–27.2) μm. Oocysts of C. minuta sp.nov. from 1/2 Lioheterodon madagascariensis Duméril and Bibron, 1854 were small and spherical, 11.6 (9.6–13.2) μm. Oocysts of C. serpentis sp.nov. from 1/2 L. madagascariensis (type host), 2/3 M. mahfalensis, and 3/4 Madagascarophis colubrinus were spherical to subspherical, 17.1 × 17.0 (13.6–20.0 × 13.6–20.0) μm. Oocysts of Eimeria furmani sp. nov. from 2/5 Hemidactylus frenatus Schlegel, 1836 measured 20.5 × 16.9 μm and oocysts of Isospora frenatus sp.nov. from 1/5 H. frenatus were large and ellipsoidal, 31.9 × 26.4 μm. In addition, oocysts of a Cryptosporidium species from 1/4 Chamaeleo lateralis Gray, 1831 were seen, and measured 5.5 × 4.8 μm, and sporocysts of three separate Sarcocystis species were noted. Sporocysts from 1/1 Lioheterodon gaeyi Mocquard, 1905 measured 9.2 × 7.9 (8.2–9.8 × 7.2–8.4) μm, those from 1/4 M. colubrinus 9.5 × 7.2 (8.8–9.8 × 6.2–8.0) μm, and those from 1/6 Mimophis mahfalensis 12.0 × 9.1 (11.2–12.8 × 8.6–9.61) μm.

APA, Harvard, Vancouver, ISO, and other styles

40

Mahmud, Muthia Elma, Erdina Lulu Atika Rampun, Aulia Rahma, Amalia Enggar Pratiwi, Chairul Abdi, and Raisa Rossadi. "Effect of Two Stages Adsorption as Pre-Treatment of Natural Organic Matter Removal in Ultrafiltration Process for Peat Water Treatment." Materials Science Forum 988 (April 2020): 114–21. http://dx.doi.org/10.4028/www.scientific.net/msf.988.114.

Full text

Abstract:

Natural Organic Matter (NOM) content in peat water is a major problem of membrane fouling in ultrafiltration (UF). For that, two stages adsorption as pre-treatment was employed to minimize the membrane fouling of NOM content. This research was carried out to investigate the effect of two stages adsorption on ultrafiltration performance for NOM removal that remains in peat water. This method was using powdered activated carbon (PAC) dosage of 80, 160, 240, 320, 400, 480, 560, 640, 720, 800, 880 dan 960 mg.L-1. Then, Polysulfone (Psf) material was employed for Ultra filtration process. Membrane was applied in a dead-end mode with various operating pressure (1; 1.5; 2; 2.5; 3 bar). As a results, the optimum dose of PAC was 800 mg L-1 with dosage ratio of 3/4:1/4. Two stages adsorption-UF PSf provided the range from 86.9 to 92.8% of KMnO4 and 74.1-88.1% of UV254. For the experimental condition of 3 bar, the highest flux was achieved up to 39.919 L h-1.m-2.

APA, Harvard, Vancouver, ISO, and other styles

41

HOUSDEN, MARTYN. "GERMANY'S FIRST REPUBLIC." Historical Journal 44, no. 2 (June 2001): 579–85. http://dx.doi.org/10.1017/s0018246x0100190x.

Full text

Abstract:

Republik ohne Chance? Akzeptanz und Legitimation der Weimarer Republik in der deutschen Tagespresse zwischen 1918 und 1923. By Burkhard Asmuss. Berlin: Walter de Gruyter, 1994. Pp. 619. ISBN 3-110-14197-3. DM280.00.Heinrich Brüning and the dissolution of the Weimar Republic. By William L. Patch. Cambridge: Cambridge University Press, 1998. Pp. 358. ISBN 0-521-62422-3. £42.50.National identity and Weimar Germany: Upper Silesia and the eastern border, 1918–1922. By T. Hunt Tooley. Lincoln, Nebraska, and London: University of Nebraska Press, 1997. Pp. 320. ISBN 0-803-24429-0. £53.00.Reichswehr und Rote Armee, 1920–1933: Wege und Stationen einer ungewönlichen Zusammenarbeit. By Manfred Zeidler. Munich: R. Oldenbourg Verlag, 1993. Pp. 375. ISBN 3-486-55966-4. DM78.00.

APA, Harvard, Vancouver, ISO, and other styles

42

Periyannan, P., M. Beemarao, K. Karthik, S. Ponnuswamy, and K. Ravichandran. "Crystal structure, DFT and Hirshfeld surface analysis of N-acetyl-t-3-methyl-r-2,c-6-diphenylpiperidine." Acta Crystallographica Section E Crystallographic Communications 78, no. 2 (January 14, 2022): 179–83. http://dx.doi.org/10.1107/s2056989022000275.

Full text

Abstract:

In the title compound [systematic name: 1-(3-methyl-2,6-diphenylpiperidin-1-yl)ethanone], C20H23NO, the piperidine ring adopts a distorted boat conformation, while the phenyl rings subtend a dihedral angle 65.1 (2)°. In the crystal, molecules are linked by C—H...O hydrogen bonds into chains extending along the b-axis direction. The DFT/B3LYP/6–311 G(d,p) method was used to determine the HOMO–LUMO energy levels. A Hirshfeld surface analysis was conducted to verify the contributions of the different intermolecular interactions, indicating that the important contributions to the crystal packing are from H...H (73.2%), C...H (18.4%) and O...H (8.4%) interactions.

APA, Harvard, Vancouver, ISO, and other styles

43

Chadwick, Owen. "Theologische Realenzyklopädie, 15. Heinrich H.-Ibsen. Edited by Gerhard Müller. Pp. 808 + plates. Berlin: Walter de Gruyter, 1986. DM 320. 3 11 008585 2." Journal of Ecclesiastical History 39, no. 1 (January 1988): 157. http://dx.doi.org/10.1017/s002204690003949x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Mainuddin, Rolin G. "Israel’s Nuclear Dilemma, by Yair Evron. 327 pages, notes, bibliography, index. Ithaca, NY: Cornell University Press, 1994. $42.50 (Cloth) ISBN 0-8014-3031-3." Middle East Studies Association Bulletin 33, no. 2 (1999): 241–42. http://dx.doi.org/10.1017/s0026318400039936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Tzilas, Vasilios, Argyris Tzouvelekis, Evangelos Bouros, Theodoros Karampitsakos, Maria Ntassiou, Eleni Avdoula, Athena Trachalaki, Katerina Antoniou, Ganesh Raghu, and Demosthenes Bouros. "Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study." ERJ Open Research 6, no. 4 (October 2020): 00152–2020. http://dx.doi.org/10.1183/23120541.00152-2020.

Full text

Abstract:

BackgroundFibrotic hypersensitivity pneumonitis (f-HP) can exhibit a progressive course similar to idiopathic pulmonary fibrosis (IPF). The lack of diagnostic guidelines and randomised controlled trials in this population represent a significant unmet need.ObjectivesTo describe our clinical experience with antifibrotics in patients with f-HP.Material and methodsRetrospective study of 30 patients diagnosed with f-HP upon re-evaluation within a multidisciplinary team discussion of 295 consecutive patients (January 2012 to December 2017) who had been diagnosed initially with IPF at outside facilities and were referred to our centres.ResultsPirfenidone was initially administered to 14 (46.7%) patients and nintedanib to 16 (53.3%) patients. There were 26 (86.7%) males, with mean±sd age 70.2±8.4 years. The annual rate of decline in forced vital capacity (FVC) % predicted over the 3-year treatment period adjusted for baseline FVC % pred measurement was 4.2% (95% CI 1.9–6.6%, p=0.001) and 7.5% (95% CI 3.3–11.7%; p=0.001) in imputation analysis. The annual rate of decline in diffusing capacity of the lung for carbon monoxide (DLCO) % predicted throughout the 3-year treatment period adjusted for baseline DLCO % pred was 5.7% (95% CI 3.1–8.4%, p<0.001) and 5.8% (95% CI 3.4–8.1%, p<0.001) in imputation analysis. The nature of adverse events was related to the type of antifibrotic agent administered.ConclusionIn patients with f-HP receiving antifibrotics there is a statistically significant annual decline in FVC % pred and DLCO % pred over a period of 3 years. Prospective randomised trials exceeding 1 year are warranted to determine the long-term efficacy of antifibrotics.

APA, Harvard, Vancouver, ISO, and other styles

46

Tran, Danielle, Kaz Nelson, and Muna Irfan. "809 Innovative electronic sleep mitigation tool for medical trainees." Sleep 44, Supplement_2 (May 1, 2021): A315—A316. http://dx.doi.org/10.1093/sleep/zsab072.806.

Full text

Abstract:

Abstract Introduction The ACGME (Accreditation Council for Graduate Medical Education) has been advocating for training of medical learners in sleep and fatigue mitigation, in attempt to enhance their wellbeing. While some educational programs include a one-time sleep didactic, prone to being overlooked, there is need for an educational resource which can be accessible to the learners throughout their training span. The trainees’ needs and readiness to learn may vary from time to time, therefore, continued access to educational resources can be very beneficial. Methods An electronic tool was created on Coggle, comprising of educational resources and content on the basic tenets of sleep quality, regulation, effects of deprivation and strategies to mitigate these effects. Links to free resources made available by AASM, such as “Choose Sleep,” were also included. The sleep resources were then incorporated in the overall continuum of Graduate Medical Education (GME) resources available to trainees, and was advertised in newsletters, incorporated in orientations (n=324) and wellness sessions (n=254). The GME Institutional Quality of Life data was obtained in 2018–2019 and in 2020 to ascertain baseline and post-intervention measures of wellness, workload and burn-out in trainees. Results Data collected in 2020, after introduction of Coggle, demonstrated: 1) A 4% increase of residents (n=1041) would rate their workload as “just right.” 2) A 9% increase of residents (n=1040) said their personal health and wellbeing was “very good” and “good.” 3) A 12% decrease of residents (n=1040) said they felt burned out at work. 4) A 5% decrease of residents (n=1037) said they felt they had become more calloused towards people since they first started training. Conclusion The analysis of learners’ feedback demonstrated that access to sleep training resources on a continuous, on-demand basis improved trainees’ personal health and wellbeing. The positive impact was sustained despite unprecedented stress caused by the COVID-19 pandemic. Future steps include: 1) Moving the electronic tool to a more advanced platform with analytical capabilities. 2) Obtaining longitudinal data to assess the impact of the electronic tool on medical trainees’ sleep parameters. 3) Sharing the electronic tool with other organizations to improve wellbeing of all medical trainees and health professionals. Support (if any):

APA, Harvard, Vancouver, ISO, and other styles

47

Mukhtar, Aamir, and De Liang Zhang. "Mechanical Behaviour of Ultrafine Grained Cu and Cu-(2.5 and 5) Vol.%Al₂O₃ Composites Produced by Powder Compact Forging." Advanced Materials Research 275 (July 2011): 170–73. http://dx.doi.org/10.4028/www.scientific.net/amr.275.170.

Full text

Abstract:

Nanostructured Cu-(2.5 and 5)vol.%Al2O3 composite powders were produced from a mixture of Cu powder and Al2O3 nanopowder using high energy mechanical milling, and then compacted by hot pressing. The Cu and Cu-Al2O3 composite powder compacts were then forged into disks at temperatures in the range of 500-800°C to consolidate the Cu and Cu-Al2O3 composite powders. Tensile testing of the specimens cut from the forged disks showed that the Cu forged disk had a good ductility (plastic strain to fracture: ~15%) and high yield strength of 320 MPa, and the Cu-(2.5 and 5)vol.%Al2O3 composite forged disks had a high fracture strength in range of 530-600 MPa, but low ductility.

APA, Harvard, Vancouver, ISO, and other styles

48

Lacayo-Leñero, Dennis, Angel Gabriel Vargas-Ruiz, Olga Barrales-Benítez, Darinel Hernández-Hernández, and Andrés Valencia-Martínez. "Primary Thrombophilia in Mexico: A Single Tertiary Referral Hospital Experience." Blood 126, no. 23 (December 3, 2015): 4717. http://dx.doi.org/10.1182/blood.v126.23.4717.4717.

Full text

Abstract:

Abstract Background: Thrombophilia is a complex hypercoagulable state that predisposes to thrombosis. Several thrombophilia reports have been conducted in Mexicans with lack of statistical significance. The objective of this study was to describe the prevalence of primary thrombophilia in a tertiary referral hospital in Mexico. Material and methods: Retrospective study of patients referred for primary thrombophilia between January 2011 and May 2015.. Thrombophilia study included: MTHFR C677T, anti-phopholipid antibodies, protein C, protein S, antithrombin, factor VIII, factor V Leiden, prothrombin mutation G20210A, APCR, JAK2 V617F, homocysteine. We used descriptive statistics according to the distribution of the variables. We used measures of central tendency and dispersion: average, median. All analyses were performed using the SPSS for Windows 20.0® Results: We identified 224 patients referred for thrombophilia testing in a 4 year period. At the time of statistical analysis 129 patients were excluded for lacking data.Ninety five patients were included.Median age at onset was 36 years. (Table 1) Nine of 60 (15%) female patients reported previous use of contraceptives and 13/60 (21.6%) reported previous obstetric morbidity. (Table 2). We identified at least one anomaly related with thrombophilia in 90/95 patients (94.7%). Eighty patients (84.1%) presented the MTHFR C677T polymorphism; heterozygous 51/95 (53.6%) presenting with hyperhomocysteinemia 18/51 (35.2%) and homozygous 29/95 (30.5%) presenting with hyperhomocysteinemia 10/29 (34.4%).Factor V Leiden was found in 5/95 (5.2%) heterozygous. It co-occurred with APCR in 3/5 cases (60%).In 44 patients we found an isolated anomaly associated with thrombophilia (46.3%). In 51/95 (53.6%) we identified co-occurring anomalies associated with thrombophilia. (Table 3). The median of co-occurring anomalies was 2 (2-4). Conclusions: The MTHFR C677T polymorphism has a very high prevalence in Mexicans compared to the low prevalence of anticoagulant protein deficiency and factor V Leiden mutation. Table 1. Demographic characteristics. Demographic characteristics No. Patients (%) -Gender Male Female Total 35 (36.8) 60 (63.1) 95 (100) -Age Median years (range) 36 (17-75) -Family history of thrombosis -Cardiovascular risk factors Arterial Hypertension Diabetes mellitus Dyslipidemia Smoking 15 (15.7) 13 (13.6) 11 (11.5) 13 (13.6) 15 (15.7) -Surgery related thrombosis 3 (3.1) -Cancer related thrombosis 3 (3.1) -Autoimmune disease SLE Other autoimmune disease 11 (11.5) 3 (3.1) 8 (8.4) SLE: Systemic Lupus Erythematosus. Table 2. Thrombosis characteristics. Thrombosis characteristics No. Patients (%) -Thrombotic events Median (range) 1 (1-4) -Affected territory Venous Arterial Mixed 80 (84.2) 14 (14.7) 1 (1) -Thrombophilia testing indication Age at onset <45 years. Family history of thrombosis Unusual site thrombosis Intra abdominal thrombosis Cerebral vein thrombosis Other unusual site thrombosis Recurrent thrombosis Obstetric morbidity More than one indication for testing 91 (95.7) 77 (81) 15 (15.7) 48 (50.5) 25/48 (52) 11/48 (22.9) 12/48 (25) 26 (27.3) 13/60 (21.6) 62 (65.2) -Treatment VKA LMWH Clopidogrel NOAC's ASA None ND 44 (46.3) 3 (3.1) 1 (1) 8 (8.4) 14 (14.7) 6 (6.3) 19 (20) VKA: Vitamin K Antagonist LMWH: Low Molecular Weight Heparin; NOAC's: New oral anticoagulants; ASA: acetylsalicylic acid. ND: Not described. Table 3. Results of thrombophilia anomalies. TROMBOPHILIA TOTAL FREQUENCY ISOLATED FREQUENCY CO-OCCURRING WITH ANOTHER THROMBOPHILIA ANOMALY. -MTHFR C677T heterozygous 51/95 (53.6%). 22/51 (43.1%) 29/51 (56.8%) -Hyperhomocysteinemia 36/95 (37.8%). 6/36 (16.6%) 30/36 (83.3%) -MTHFR C677T homoczygous 29/95 (30.5%). 14/29 (48.2%) 15/29 (51.7%) -APCR 13/95 (13.6%). 0 13/13 (100%) -F V Leiden G1691A 5/95 (5.2%) 0 5/5 (100%) -Protein C deficiency 5/95 (5.2%) 0 5/5 (100%) -Elevated FVIII levels (>150%) 4/95 (4.2%) 0 4/4 (100%) -Protein S deficiency 3/95 (3.1%) 1/3 (33.3%) 2/3 (66.6%) -APS 3/95 (3.1%) 0 3/3 (100%) -Prothrombin G20210A 2/95 (2.1%). 0 2/2 (100%) -JAK2V617F 1/95 (1.0%) 1/1 (100%) 0 -Antithrombin deficiency 0 0 0 MTHFR: methylentetrahidrofolate reductase; APCR: Activated protein C resistance; APS: Antiphospholipid syndrome. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

49

Jain, M., A. Chatterjee, J. Mohapatra, D. Bandhyopadhyay, K. Ghoshdostidar, U. Bhatnagar, H. Patel, et al. "325 Identification of a novel efficacious and safe poly (ADP-ribose) polymerase (PARP) and tankyrase inhibitor for treatment of various types of solid tumors." European Journal of Cancer 51 (September 2015): S63. http://dx.doi.org/10.1016/s0959-8049(16)30190-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

WALSH, MARGARET. "Dorothy Sue Cobble (ed.), The Sex of Class: Women Transforming American Labor (Ithaca: Cornell University Press, 2007, $65.00 cloth, $22.50 paper). Pp. xii+327. isbn978 0 8014 4322 0, 978 0 8014 8943 3." Journal of American Studies 42, no. 2 (August 2008): 361–62. http://dx.doi.org/10.1017/s0021875808004817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic '321.804 3'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles